Remdesivir, an investigational drug being studied for treatment of severe COVID-19, is available for use in the United States after receiving Emergency Use Authorization (EUA) by the FDA.
A limited supply of remdesivir has been distributed from the federal government to the Wisconsin Department of Health Services, for distribution to Wisconsin hospitals. DHS is making the drug available for hospitalized patients who meet clinical criteria specified under the EUA.
Hospitals can request one or more cases, each containing 40 single-dose vials of remsdesivir, from the State Emergency Operations Center, for next-day delivery. If more requests are received than can be filled, the state will give priority to hospitals currently caring for the highest number of COVID-19 patients.
Providers may access patient COVID-19 lab results via the Public Health Analysis Visualization and Reporting (PHAVR) web portal. View instructions here.
Exact Science COVID-19 results are also available to Epic customers via Care Everywhere
CDC Mini Webinar Series for Long-Term Care Staff: This series of 5 short webinars reviews basic infection prevention steps including: proper use of PPE and facemasks, how and when to perform hand hygiene, how and when to clean surfaces, and the need to check residents and staff daily for symptoms of COVID-19.